Cryptococcal meningitis (CM) constitutes a significant source of mortality in resource-limited regions. Cryptococcal antigen (CRAG) can be detected in the blood before onset of meningitis. We sought to determine the cost-effectiveness of implementing CRAG screening using the recently developed CRAG lateral flow assay in Uganda compared to current practice without screening.
A decision-analytic model was constructed to compare two strategies for cryptococcal prevention among people living with HIV with CD4 < 100 in Uganda: No cryptococcal screening vs. CRAG screening with WHO-recommended preemptive treatment for CRAG-positive patients. The model was constructed to reflect primary HIV clinics in Uganda, with a cohort of HIV-infected patients with CD4 < 100 cells/uL. Primary outcomes were expected costs, DALYs, and incremental cost-effectiveness ratios (ICERs). We evaluated varying levels of programmatic implementation in secondary analysis.
CRAG screening was considered highly cost-effective and was associated with an ICER of $6.14 per DALY averted compared to no screening (95% uncertainty range: $-20.32 to $36.47). Overall, implementation of CRAG screening was projected to cost $1.52 more per person, and was projected to result in a 40% relative reduction in cryptococcal-associated mortality. In probabilistic sensitivity analysis, CRAG screening was cost-effective in 100% of scenarios and cost saving (ie cheaper and more effective than no screening) in 30% of scenarios. Secondary analysis projected a total cost of $651,454 for 100% implementation of screening nationally, while averting 1228 deaths compared to no screening.
CRAG screening for PLWH with low CD4 represents excellent value for money with the potential to prevent cryptococcal morbidity and mortality in Uganda.
WHO U. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report. World Health Organization. 2011; 53. Available at: http://www.who.int/hiv/topics/treatment/data/en/index2.html. Accessed 14 Jan 2015.
Chang LW, Phipps WT, Kennedy GE, Rutherford GW. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev. 2005;2005(3):CD004773.
McKenney J, Smith RM, Chiller TM, et al. Prevalence and correlates of cryptococcal antigen positivity among AIDS patients--United States, 1986-2012. MMWR Morb Mortal Wkly Rep. 2014;63(27):585–7. PubMed
WHO. Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-infected Adults, Adolescents and Children. 2011.
Pac L, Horwitz M, Namutembi A. Integrated Pre-Antiretroviral Therapy Screening and Treatment for Tuberculosis and Cryptococcal Antigenemia. JAIDS. 2015. (in press).
Pac L, Horwitz MM, Namutebi AM, Auerbach BJ, Semeere A, Namulema T, et al. Implementation and operational research: integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia. J Acquir Immune Defic Syndr. 2015;68(5):e69–76. CrossRefPubMedPubMedCentral
UNAIDS. "The HIV/AIDS Uganda Country Progress Report 2014" http://www.unaids.org/sites/default/files/country/documents/UGA_narrative_report_2015.pdf. Accessed 14 May 2016
Joint Medical Store. Catalogue and Price Indicator. http://www.jms.co.ug/sites/default/files/resources/Catalogue%20Feb%202015_light%20version_0.pdf. Accessed 4 Mar 2016.
Ninci A, Ocakacon R. How Much Do Lab Tests Cost? Analysis of Lacor Hospital Laboratory Services. Health Policy Dev. 2004;2(2):44–150.
Moreland S, Namisango E, Paxton A, Powell R. Measure Evaluation - The costs of HIV treatment, care, and support services in Uganda: a technical report. 2013.
WHO. Cost-Effectiveness Thresholds. Available at: http://www.who.int/choice/costs/CER_levels/en/. Accessed 4 Nov 2014.
World_Bank. GDP per capita by country.Available at: http://data.worldbank.org/indicator/NY.GDP.PCAP.CD?order=wbapi_data_value_2013+wbapi_data_value+wbapi_data_value-last&sort=asc. Accessed 4 Nov 2014.
Fiani D, Vedastus A, Neborak J et al. Maximizing detection and improving outcomes of cryptococcosis in rural Tanzania. 2016. Available at: http://www.croiconference.org/sites/default/files/posters-2016/760_0.pdf Accessed 14 Jun 2016
McKenney J, Bauman S, Neary B, et al. Prevalence, Correlates, and Outcomes o Cryptococcal Antigen Positivity Among Patients With AIDS, United States, 1986–2012. Clin Infect Dis. 2015;60(6):959–65.
Meya DB, Manabe YC, Castelnuovo B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis. 2010;51(4):448–55. CrossRefPubMedPubMedCentral
WHO. Age-Specific Disability Weights for untreated and treated forms of sequelae included in the Global Burden of Disease Study. http://www.who.int/healthinfo/bodreferencedisabilityweights.xls. Accessed Jun 10, 2014.
- Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II